1cBio and Lee’s Pharm Partner on PARP1 Inhibitor OC-3
San Francisco, California, and Hong Kong, China, September 9, 2026 1cBio and Lee’s Pharmaceutical Holdings Limited (Lee’s Pharm) have...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
San Francisco, California, and Hong Kong, China, September 9, 2026 1cBio and Lee’s Pharmaceutical Holdings Limited (Lee’s Pharm) have...
Cambridge, UK, September 1, 2026 AstraZeneca has announced positive high-level results from the Phase III SANOVO trial, showing that...
COPENHAGEN, Denmark, August 31, 2026 Ascendis Pharma A/S and BioMarin Pharmaceutical Inc. have entered into a binding term sheet...
INGELHEIM, Germany and WALTHAM, Mass., May 12, 2026 Boehringer Ingelheim has entered into a global licensing agreement with Immunitas...
SAN FRANCISCO, March 3, 2026 Jaguar Health has secured an additional $3 million payment from Future Pak under a...
